Financial Advocates Investment Management Crispr Therapeutics Ag Transaction History

Financial Advocates Investment Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 04, 2021	SELL	$110.2 - $156.64 $333,355 - $473,835	-3,025 Closed	0 $0
Q2 2021 Aug 03, 2021	BUY	$100.84 - $161.89 $305,041 - $489,717	3,025 New	3,025 $490,000
Q1 2021 May 10, 2021	SELL	$110.72 - $210.04 $152,461 - $289,225	-1,377 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $40,392 - $87,827	507 Added 58.28%	1,377 $211,000
Q4 2018 Feb 14, 2019	BUY	$22.73 - $42.34 $2,682 - $4,996	118 Added 15.69%	870 $24,000
Q3 2018 Nov 14, 2018	BUY	$44.35 - $65.71 $33,351 - $49,413	752 New	752 $0

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Financial Advocates Investment Management, based on Form 13F filings with the SEC.

Stay updated on Financial Advocates Investment Management with notifications on news.